NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Abstract Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologics and standard-of-care therapies. Tezepelumab is a...

Full description

Bibliographic Details
Main Authors: Andrew Menzies-Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist, Sandhia Ponnarambil, Primal Kaur, Gennaro Ruberto, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Respiratory Research
Subjects:
Clinical trial
Severe asthma
Tezepelumab
Thymic stromal lymphopoietin
Online Access:http://link.springer.com/article/10.1186/s12931-020-01526-6

Internet

http://link.springer.com/article/10.1186/s12931-020-01526-6

Similar Items